Back to Authors

Malkasian, Shant

https://orcid.org/0000-0002-6478-4321

Mayo Clinic

UC San Diego Health System

Citations 1

The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention
Verpalen, Victor A. , Coerkamp, Casper F. , Malkasian, Shant , Gaillard, Émilie , Beverloo, C Y Y, Ibrahim, Shirin , Vijver, Willem van de, Claessen, Bimmer E P M , Knaapen, Paul, Takx, R A P, Planken, R Nils, Stroes, Erik S G, Jp, Henriques, Nurmohamed, N S, Takx, Richard A. P. , Beverloo, Cheyenne Y Y , van de Vijver, Willem R , Knaapen, Paul , Takx, Richard A P , Planken, R Nils , Henriques, José P S , Nurmohamed, Nick S , Gaillard, Emilie L, Knaapen, Paul , Planken, R. Nils , Stroes, Erik S.G.

European Journal of Preventive Cardiology | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwag243 Get It

Abstract Aims Lipoprotein(a) [Lp(a)] is a causal risk factor for cardiovascular events. However, the effect of Lp(a) on coronary plaque composition and high-risk plaque features has not been fully characterized. This study aimed to investigate the association between Lp(a) and coronary atherosclerotic plaque phenotype at the plaque level. Methods and results This study included 710 patients who underwent coronary computed tomography angiography (CCTA) and had Lp(a) measured between 2008 and 2024. CCTA scans were analysed with a previously validated artificial intelligence-based algorithm (AI-QCT, Cleerly Inc.). The association of Lp(a) with non-calcified and calcified plaque volumes and HRP features was evaluated at the plaque level using generalized estimating equation models adjusted for traditional cardiovascular risk factors. Among the 710 patients, the mean age was 56 ± 10 years and 379 (53%) were male. In total, 3642 plaques were identified. In the adjusted plaque-level analysis, elevated Lp(a) (≥150 nmol/L) was associated with an increase in non-calcified plaque volume per plaque (P = 0.009), but not with an increase in calcified plaque volume (P = 0.81). Furthermore, elevated Lp(a) (≥150 nmol/L) was strongly associated with the presence of high-risk plaque at the plaque level (adjusted odds ratio: 1.78, 95% CI: 1.25–2.54, P = 0.001), whereas low-density lipoprotein-cholesterol and high-sensitivity C-reactive protein were not (P > 0.05). Conclusion In this plaque-level CCTA study of 3642 individual plaques, elevated Lp(a) levels were independently associated with increased non-calcified plaque volume and with the presence of high-risk plaque, but not with calcified plaque volume. These findings elucidate the impact of Lp(a) on unstable plaque phenotypes, even in patients without prior cardiovascular events.